Featured Publications
Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes
Kotlyar A, Seifer D. Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes. Reproductive Biology And Endocrinology 2023, 21: 70. PMID: 37528417, PMCID: PMC10391774, DOI: 10.1186/s12958-023-01120-7.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeOvarian hyperstimulation syndromeOvarian stimulationStimulation protocolFrozen embryo transfer cyclesVitamin D repletionGnRH agonist triggerVitamin D levelsEmbryo transfer cyclesOvarian stimulation protocolsAntagonist cyclesHyperstimulation syndromeHypertensive disordersIVF cyclesPCOS patientsAgonist triggerOvarian syndromeOocyte yieldD levelsImproved outcomesPregnancy rateCommon causeIVF performanceTherapeutic courseInfertile couples
2018
Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility
Butts SF, Seifer DB, Koelper N, Senapati S, Sammel MD, Hoofnagle AN, Kelly A, Krawetz SA, Santoro N, Zhang H, Diamond MP, Legro RS, Network E. Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility. The Journal Of Clinical Endocrinology & Metabolism 2018, 104: 369-378. PMID: 30085176, PMCID: PMC6300410, DOI: 10.1210/jc.2018-00750.Peer-Reviewed Original ResearchConceptsVitamin D deficiencyPolycystic ovary syndromeD deficiencyEarly pregnancy lossOvarian stimulationUnexplained infertilityLive birthsPregnancy lossDiagnosis of PCOSMultiple Intrauterine GestationsOvarian stimulation outcomesRetrospective cohort studyInvestigation of womenBanked seraPPCOS IICohort studyIntrauterine gestationOvary syndromeInfertile womenInfertility diagnosisPregnant subjectsElevated riskImportant treatmentReproductive outcomesTrial data
2017
Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine
Kushnir VA, Seifer DB, Barad DH, Sen A, Gleicher N. Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine. Journal Of Assisted Reproduction And Genetics 2017, 34: 1105-1113. PMID: 28643088, PMCID: PMC5581791, DOI: 10.1007/s10815-017-0977-4.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Mullerian HormoneFemaleHumansOvarian FollicleOvulation InductionPolycystic Ovary SyndromeReproductionReproductive MedicineConceptsAnti-Müllerian hormonePolycystic ovarian syndromePotential therapeutic applicationsReproductive medicineOnset of menopauseNew potential therapeutic applicationsOvarian follicular developmentTherapeutic applicationsSpecific disease conditionsPromising therapeutic applicationOvarian syndromeOvulation inductionFertility preservationPharmacologic agentsFollicular developmentHormone analogueReproductive tractDisease conditionsTherapeutic usesTGF-beta superfamilyAntagonist functionImportant regulatorDiagnostic purposesGonadal tissueKey regulator
2015
Assessing ovarian response: antral follicle count versus anti-Müllerian hormone
Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Reproductive BioMedicine Online 2015, 31: 486-496. PMID: 26283017, DOI: 10.1016/j.rbmo.2015.06.015.Peer-Reviewed Original ResearchConceptsAntral follicle countAnti-Müllerian hormoneAMH levelsOvarian reserveFollicle countOvarian responseFollicle numberPredictive valueSerum anti-Müllerian hormoneGood predictive valuePersonalization of treatmentGold standard biomarkerOvarian stimulationExogenous gonadotrophinsMenstrual cyclePoor responseHormone biomarkersOocyte numberUltrasound biomarkersBiomarkersAmerican SocietyGood responseSame ageHormoneStimulation
2014
Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis
Tal R, Tal O, Seifer BJ, Seifer DB. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertility And Sterility 2014, 103: 119-130.e3. PMID: 25450298, DOI: 10.1016/j.fertnstert.2014.09.041.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEmbryo ImplantationFemaleFertilization in VitroHumansInfertility, FemaleMiddle AgedObservational Studies as TopicOvarian ReserveOvaryOvulation InductionPregnancyPregnancy OutcomePregnancy RatePrevalenceReproducibility of ResultsRisk FactorsSensitivity and SpecificityYoung AdultConceptsPredictor of implantationClinical pregnancy rateAntimüllerian hormoneClinical pregnancyOvarian reservePregnancy rateOdds ratioIVF/intracytoplasmic sperm injectionSystematic reviewSerum AMH levelsPolycystic ovary syndromeReproductive technologiesIntracytoplasmic sperm injectionNondonor cyclesAMH levelsOvary syndromeImplantation rateDiagnostic odds ratioObservational studyMAIN OUTCOMEClinical utilitySperm injectionPregnancyAssisted conceptionFertility treatmentFollicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation
Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reproductive Biology And Endocrinology 2014, 12: 82. PMID: 25141961, PMCID: PMC4150963, DOI: 10.1186/1477-7827-12-82.Peer-Reviewed Original ResearchMeSH KeywordsAdultCohort StudiesDown-RegulationFamily CharacteristicsFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleInfertility, MaleMaleNew York CityOocyte RetrievalOvarian ReserveOvulation InductionPlacenta Growth FactorPolycystic Ovary SyndromePregnancyPregnancy ProteinsPregnancy RateProspective StudiesUp-RegulationVascular Endothelial Growth Factor Receptor-1ConceptsNon-PCOS controlsPCOS womenOvarian stimulationSFlt-1 levelsAnti-Mullerian hormonePlacental growth factorVascular endothelial growth factorFollicular fluidOvarian syndromeSFlt-1Growth factorSoluble receptor sFlt-1BackgroundPolycystic ovarian syndromeControlled ovarian stimulationPlGF/sFltDay of hCGProspective cohort studyPolycystic ovarian syndromeNumber of oocytesEndothelial growth factorVEGF family membersCohort studyOocyte retrievalPlGF levelsVascular changesCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome
2013
Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation
Tal R, Seifer DB, Shohat-Tal A, Grazi RV, Malter HE. Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. Fertility And Sterility 2013, 100: 538-543. PMID: 23684116, DOI: 10.1016/j.fertnstert.2013.04.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, CDCase-Control StudiesEndoglinFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleOvarian Hyperstimulation SyndromeOvulation InductionPolycystic Ovary SyndromeReceptors, Cell SurfaceSperm Injections, IntracytoplasmicTransforming Growth Factor beta1UltrasonographyYoung AdultConceptsPolycystic ovarian syndromeSerum soluble endoglinDay of hCGSoluble endoglinFollicular fluidTGF-β1Oocyte retrievalOvarian stimulationHCG administrationControl womenDay 3Pathogenesis of PCOSNon-PCOS control groupProspective case-control studyNon-PCOS controlsSerum TGF-β1Non-PCOS womenPolycystic ovary syndromeTGF-β1 levelsReproductive technology unitCase-control studyGrowth factor-β1Day of retrievalOvarian hyperstimulationOvarian syndrome
2012
High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers
Leader B, Hegde A, Baca Q, Stone K, Lannon B, Seifer DB, Broekmans F, Baker VL. High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. Fertility And Sterility 2012, 98: 1037-1042. PMID: 22771028, DOI: 10.1016/j.fertnstert.2012.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAnti-Mullerian HormoneChemistry, ClinicalEstradiolFemaleFertilityFollicle Stimulating Hormone, HumanHumansMenstrual CycleMiddle AgedOocytesOvulation InductionPredictive Value of TestsPrognosisReference StandardsReproductive MedicineRetrospective StudiesUnited StatesYoung AdultConceptsYears of ageFSH valuesSerum AMHAntimüllerian hormoneAMH valuesFertility centerCut pointsDay 2Clinical discordanceMenstrual cycle day 2Follicle-stimulating hormone levelsCycle day 2Reference laboratoryFollicle-stimulating hormoneLarger patient populationSingle reference laboratoryFrequency of discordanceAge-dependent fashionClinical cut pointsSame serum samplesOvarian stimulationPatient populationAMH testingMenstrual cycleHormone levels
2011
Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve
Buyuk E, Seifer DB, Illions E, Grazi RV, Lieman H. Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve. Fertility And Sterility 2011, 95: 2364-2368. PMID: 21529798, DOI: 10.1016/j.fertnstert.2011.03.081.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersBody Mass IndexCross-Sectional StudiesDown-RegulationFemaleFollicle Stimulating Hormone, HumanHumansInfertility, FemaleLinear ModelsNew YorkOocyte RetrievalOverweightOvulationOvulation InductionReproductive Techniques, AssistedRisk AssessmentRisk FactorsConceptsElevated body mass indexNormal ovarian reserveBody mass indexSerum AMH levelsOvarian reserveNumber of oocytesAMH levelsObese womenInfertile womenMass indexHormone levelsDay 3 serum FSH levelsSerum anti-Mullerian hormone (AMH) levelsAnti-Mullerian hormone levelsLow serum AMH levelsSerum antimullerian hormone (AMH) levelsNormal body mass indexAntimullerian hormone levelsReproductive technology cyclesSerum FSH levelsDiminished ovarian reserveIU/L.Cross-sectional studyOvarian hyperstimulationIVF cyclesRandom anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels
Buyuk E, Seifer DB, Younger J, Grazi RV, Lieman H. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertility And Sterility 2011, 95: 2369-2372. PMID: 21497340, DOI: 10.1016/j.fertnstert.2011.03.071.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersChi-Square DistributionEmbryo TransferFemaleFertilization in VitroFollicle Stimulating Hormone, HumanFollicular PhaseHumansInfertility, FemaleNew YorkOocyte RetrievalOvulationOvulation InductionPregnancyPregnancy RateRetrospective StudiesTime FactorsTreatment OutcomeUp-RegulationConceptsAnti-Müllerian hormoneNumber of oocytesClinical pregnancy rateSerum AMH levelsDiminished ovarian reserveAMH levelsFSH levelsDay 3 embryosElevated FSHOvarian responseART cyclesPregnancy rateEarly follicular FSH levelsFollicle-stimulating hormone levelsSerum anti-Müllerian hormoneCycle cancellation rateSerum FSH levelsReproductive technology programCycle cancellationOvarian reserveRetrospective studyHormone levelsMAIN OUTCOMECancellation rateRandom sera
2007
Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance
Seifer DB, MacLaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertility And Sterility 2007, 88: 539-546. PMID: 17559842, DOI: 10.1016/j.fertnstert.2007.02.014.Peer-Reviewed Original ResearchConceptsPolycystic ovarian diseaseMullerian Inhibiting SubstanceOvarian reserveOvulation inductionInhibiting SubstanceDiagnosis of PCODRisk of OHSSOvarian growth factorsWidespread clinical useOvarian hyperstimulationOvarian diseaseOvarian functionMEDLINE reviewClinical significanceIntracycle variabilityEarly markerClinical useConventional markersDiagnostic markerGrowth factorSpecific cutIntercycle variabilityDifferent assaysMarkersDiagnosis
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation induction
2002
Practice patterns among board-certified reproductive endocrinologists regarding high-order multiple gestations: a united states national survey.
Hock DL, Seifer DB, Kontopoulos E, Ananth CV. Practice patterns among board-certified reproductive endocrinologists regarding high-order multiple gestations: a united states national survey. Obstetrics And Gynecology 2002, 99: 763-70. PMID: 11978285, DOI: 10.1016/s0029-7844(02)01950-6.Peer-Reviewed Original ResearchMeSH KeywordsCounselingEndocrinologyFemaleFertilization in VitroHealth SurveysHumansInformed ConsentInsemination, ArtificialOvarian FollicleOvulation InductionPractice Patterns, Physicians'PregnancyPregnancy Reduction, MultifetalPregnancy, High-RiskPregnancy, MultipleReproductive MedicineRisk FactorsSuperovulationSurveys and QuestionnairesUnited StatesConceptsHigh-order multiple gestationsMultiple gestationsOverall pregnancy rateReproductive endocrinologistsIntrauterine inseminationOvulation inductionPractice patternsBoard-certified reproductive endocrinologistsHigher-order pregnanciesCurrent practice managementSurvey response ratePregnancy rateMost physiciansGestationResponse ratePractitioner demographicsEndocrinologistsInformed consentSequelaeIncidencePractice managementRiskInseminationInductionQuestionnaireEarly follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles
Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertility And Sterility 2002, 77: 468-471. PMID: 11872196, DOI: 10.1016/s0015-0282(01)03201-0.Peer-Reviewed Original ResearchConceptsOvarian responseMIS concentrationsReproductive technology cyclesGreater serum concentrationsGroup of womenOvulation inductionSerum concentrationsMaximum serumRetrospective analysisMAIN OUTCOMESubstance levelsSerum MISSerum samplesMI levelsWomenMature oocytesTechnology cyclesReproductive technologiesOocytesSerumART programsGroupIVFGreater number
1999
Infertility treatment and informed consent: current practices of reproductive endocrinologists.
Houmard BS, Seifer DB. Infertility treatment and informed consent: current practices of reproductive endocrinologists. Obstetrics And Gynecology 1999, 93: 252-7. PMID: 9932565, DOI: 10.1016/s0029-7844(98)00389-5.Peer-Reviewed Original ResearchMeSH KeywordsData CollectionFemaleHumansInfertility, FemaleInformed ConsentOvarian NeoplasmsOvulation InductionPractice Patterns, Physicians'ConceptsOvulation inductionCurrent practice patternsInfertility treatmentOvarian cancerReproductive endocrinologistsInformed consentIntrauterine inseminationPractice patternsMost physiciansBoard-certified reproductive endocrinologistsReproductive technologiesPatients of risksOvarian cancer riskLength of treatmentLogistic regression analysisMajority of physiciansAssisted Reproductive TechnologyInvasive therapyCancer riskVerbal consentPossible associationEndocrinologistsCancerPhysiciansCommon changes
1998
The detection of diminished ovarian reserve in infertile women
Sharara F, Scott R, Seifer D. The detection of diminished ovarian reserve in infertile women. American Journal Of Obstetrics And Gynecology 1998, 179: 804-812. PMID: 9757994, DOI: 10.1016/s0002-9378(98)70087-0.Peer-Reviewed Original ResearchMeSH KeywordsAgingFemaleFertilization in VitroFollicle Stimulating HormoneHumansInfertility, FemaleOvaryOvulation InductionPregnancyPregnancy RateConceptsOvarian reserveOwn gametesDiminished ovarian reserveFetal cardiac activityLower chanceReproductive technologiesInfertility populationInfertile womenProvocative testsPregnancy lossPregnancy rateInvasive therapyHigh incidenceExpensive treatmentWomenCardiac activityLate 30sEarly 40sMultiple testingDaily challengesPregnancyUltrasonographyInfertilityTherapyClinicians
1997
Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction
Friedman C, Danforth D, Herbosa-Encarnacion C, Arbogast L, Alak B, Seifer D. Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction. Fertility And Sterility 1997, 68: 607-612. PMID: 9341598, DOI: 10.1016/s0015-0282(97)00278-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgingCobaltCohort StudiesCorpus LuteumEndothelial Growth FactorsFemaleFollicular FluidGranulosa CellsHumansHypoxiaLymphokinesMaternal AgeMiddle AgedOsmolar ConcentrationOvulation InductionPregnancyPregnancy, High-RiskRetrospective StudiesTime FactorsVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsAdvanced reproductive ageVascular endothelial growth factor/vascular permeability factorVascular permeability factorReproductive ageFollicular fluidFactor concentrationsPermeability factorFollicular fluid vascular endothelial growth factor concentrationsGranulosa cellsVascular endothelial growth factor concentrationsYoung womenRetrospective cohort studyReproductive-age womenUniversity Teaching HospitalPg/mLGrowth factor concentrationsCohort studyIVF-ETOvulation inductionHCG administrationAge womenCobalt chlorideTeaching hospitalMAIN OUTCOMEFollicular aspiration
1995
Endocrinology: Follicular fluid insulin-like growth factor-I and insulin-like growth factor-II concentrations vary as a function of day 3 serum follicle stimulating hormone*
Seifer DB, Giudice LC, Dsupin BA, Haning RV, Frishman GN, Burger HG. Endocrinology: Follicular fluid insulin-like growth factor-I and insulin-like growth factor-II concentrations vary as a function of day 3 serum follicle stimulating hormone*. Human Reproduction 1995, 10: 804-806. PMID: 7650124, DOI: 10.1093/oxfordjournals.humrep.a136042.Peer-Reviewed Original ResearchConceptsDay 3 serum follicleInsulin-like growth factorFollicular fluid concentrationsFSH groupSerum follicleIGF-IIGrowth factorFollicular fluid insulin-like growth factorMean IGF-II concentrationsFluid concentrationsMean IGF-I concentrationInsulin-like growth factor II concentrationsDay 3 FSHFollicular fluid IGFIGF-II concentrationsIGF-I concentrationsFactor II concentrationsFollicular fluid aspirationInhibin concentrationsFluid aspirationEmbryo transferFolliclesIGFHormoneGroup
1994
Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors*
Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors*. Human Reproduction 1994, 9: 792-799. PMID: 7929724, DOI: 10.1093/oxfordjournals.humrep.a138598.Peer-Reviewed Original ResearchConceptsLate ovarian hyperstimulation syndromeOvarian hyperstimulation syndromeSevere ovarian hyperstimulation syndromeNumber of oocytesHyperstimulation syndromeEarly ovarian hyperstimulation syndromePost-human chorionic gonadotrophinDifferent risk factorsStepwise logistic regressionSeries of casesDay-hCGMultiple gestationsClinical predictorsFertilization cyclesGestational sacEarly pregnancyLate presentationOestradiol concentrationsSerum concentrationsEgg retrievalRisk factorsHigh oestradiolAcute effectsChorionic gonadotrophinRetrospective analysis